MedPath

Clonidine as an additive to local anaesthetic injections around scalp.

Phase 3
Completed
Conditions
ASA I and II patients
Registration Number
CTRI/2014/10/005151
Lead Sponsor
King Edward Memorial Hospital
Brief Summary

Primary purpose is to study the duration of analgesia and intraoperative haemodynamics after addition of clonidine to scalp block with 0.25% bupivacaine. It is hypothetised that clonidine will prolong the duration of anaesthesia and provide stable intraoperative haemodynamics.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

1] 60 ASA I and II patients 2] Age 18yrs to 65 yrs 3] Glasgow coma scale 15/15 4] Patients undergoing supratentorial craniotomies under general anaesthesia.

Exclusion Criteria

1] Emergency cases 2] Patients with uncontrolled hypertension 3] Ischaemic heart disease or cardiac arrhythmias 4] Hepatic or renal disease 5] severe pulmonary disease 6] chronic alcoholism and chronic drug abusers 7] History of craniotomy 8] History of drug allergy to local anaesthetics and/or clonidine 9] patients on alpha blockers preoperatively 10] patient refusal.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Duration of postoperative analgesia24 hours
Secondary Outcome Measures
NameTimeMethod
Intraoperative haemodynamicsEvery 5 minutes from skin incision to dura opening and dura closure to skin suturing
Intraoperative requirement of fentanylintraoperative
Complications like bradycardia, hypertension etc.intraoperative

Trial Locations

Locations (1)

GSMC and King Edward Memorial Hospital, Department of anaesthesiology.

🇮🇳

(Suburban), MAHARASHTRA, India

GSMC and King Edward Memorial Hospital, Department of anaesthesiology.
🇮🇳(Suburban), MAHARASHTRA, India
Dr Anjana Wajekar
Principal investigator
919930104106
anjanawajekar@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.